The incidence, risk factors and mortality of veno-occlusive disease (VOD) were identified for 142 pediatric hematopoietic stem cell (HSC) transplant recipients with hematological malignancies (83), solid tumors (41) and nonmalignant diseases (18). This historical cohort of 142 HSC transplant patients, from January 1993 through June 2000, was assessed by chart review. Risk factors for the development of VOD and mortality were assessed by multiple logistic regression and Kaplan-Meier survival curves respectively. The incidence of VOD was 18.3% (26/142 transplants). Multivariate analysis reconfirmed the known pretransplant risk factors of induction therapy with busulfan and transplantation with matched unrelated donor cells as significant risk factors for the development of VOD. In addition, two new risk factors, positive CMV serology in the recipient and TPN provided in the 30 days prior to transplant, were identified. Mortality in transplant patients at 100 days was greater in the VODpositive group (10/26 (38.5%)) compared to the VODnegative group (11/116 (9.5%) (P ¼ 0.001)). The risk of death was 4.97 times higher with 95% CIs (2.11, 11.71) for the VOD-positive group. Decreasing the risk factors for VOD may decrease mortality in this patient population.
veno-occlusive disease; pediatric; risk factor; survival Veno-occlusive disease (VOD) is a well-recognized major hepatic complication of hematopoietic stem cell (HSC) transplantation. In children, it occurs at a rate between 1.2 and 28%. [1] [2] [3] [4] [5] [6] [7] [8] VOD is the third leading cause of death in pediatric HSC transplant patients in the immediate posttransplant period. The mortality rate ranges from 10 to 40%. 9, 10 To date, there is no proven efficacious therapy once VOD develops other than supportive care.
A diagnosis of VOD is made according to the most widely used clinical tool, the Seattle criteria. The Seattle criteria requires two of the following three physical or laboratory findings to be observed: (1) jaundice or bilirubin level 434 mmol/l; (2) hepatomegaly or right upper quadrant pain of liver origin or; (3) sudden weight gain of 45% above baseline because of either fluid accumulation or ascites. Also, any other more plausible explanation(s) for the above signs and symptoms needs to be ruled out at the time of diagnosis. 11 The clinical diagnosis is supported by histological abnormalities based on animal models and patient findings. These can be divided into early and late findings. In a rat model, there is an initial loss of sinusoidal endothelial cell fenestration with the appearance of gaps in the sinusoidal endothelial barrier. These endothelial cells round up and red blood cells get into the space of Disse beneath the endothelial cells and dissect off the sinusoids' endothelial lining. The sloughed off endothelial cells flow downstream and cause obstruction of both sinusoidal flow and microcirculation. This is further exacerbated by an influx of monocytes into the sinusoids. By the time hepatocyte necrosis is observed, the sinusoidal lining has been extensively sloughed away. Therefore, hepatocyte necrosis is indicative of the later stage of the disease process. In human histopathological specimens diagnosed with VOD, there is also extravasation of the red blood cells into the space of Disse with engorgement of the sinusoids and accumulation of extracellular material in the sinusoidal pores. There is also frank necrosis of perivenular hepatocytes. Simultaneously, there is noted widening of the subendothelial zone between the basement membrane and adventitia in hepatic central veins and sublobular veins. The later changes observed are curvilinear deposits of extracellular matrix, mostly collagen, seen in the venular subendothelial spaces and sinusoids including increased numbers of stellate cells. 12 Both blood vessel occlusion and hepatocellular injury are seen at autopsy when a patient meets the clinical criteria for VOD. In a previous study, the most common findings at autopsy included hepatic venular occlusion, hepatic venular eccentric luminal narrowing, phlebosclerosis, sinusoidal fibrosis and hepatic necrosis. 13 It is speculated that the genesis of VOD-associated lesions are related to the pretransplant cytoreductive therapy, which injures zone 3 structures of the liver including sinusoidal and venular endothelium and hepatocytes. 13 Previous attempts to identify potential risk factors for the development of VOD were carried out in predominately homogeneous pediatric populations with either specifically defined induction chemotherapy regimens or common underlying medical conditions. [1] [2] [3] [4] [5] [6] [7] [8] [9] 11 This study distinguishes itself from other studies by determining the possible risk factors for the development of VOD in a more heterogeneous pediatric population of hematopoietic stem cell recipients. This will enable physicians to counsel patients, whose disease or protocol has not been previously assessed for risk of VOD, and to assess a general level of risk that the patient may encounter. A retrospective review of 142 hematopoietic stem cell transplants in 132 separate patients consisting of both malignant and nonmalignant etiologies was performed.
Materials and methods

Patient selection
A retrospective chart review of a historical cohort consisting of 142 consecutive pediatric HSC transplants from January 1993 to June 2000 was performed and combined with pre-existing demographic data. Patient charts were reviewed for descriptive and laboratory data to identify possible risk factors for the development of VOD and for their 100-day post-transplant survival. All patients and their families were informed and had consented to be a part of research studies and protocols, which included their chemotherapy regimen and their outcome status. The study was approved by the Joint Ethics Committee for the University of Calgary and the Calgary Regional Health Authority.
Inclusion criteria
All patients transplanted through the Alberta Children's Hospital Bone Marrow Transplant Program between January 1993 and June 2000 were included in the study. Exclusion criteria included death prior to receiving the HSC transplant. No eligible patient record was excluded from the study.
The Seattle criteria were used as the diagnostic tool for VOD throughout the period of the study. The Seattle criteria for hepatic VOD requires two of the following three criteria to be present (while simultaneously ruling out any other more likely competing diagnoses). Jaundice or bilirubin level 434 mmol/l; hepatomegaly or right upper quadrant pain of liver origin, and/or sudden weight gain of 45% above baseline because of either fluid accumulation or ascites.
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The main competing diagnoses for VOD are infectious diseases and acute graft-versus-host disease (GVHD). There were no cases of CMV hepatitis diagnosed, but one case of CMV colitis was documented. No patient had features of GVHD within 7 days of the VOD diagnosis. No evidence of infection was identified within 7 days of the VOD diagnosis either. In addition to competing diagnoses being ruled out, therapy for VOD had been initiated in the form of fluid restriction and diuretic therapy in all cases.
For VOD risk factor analysis, a literature search for both adult and pediatric studies was conducted using Medline, Pubmed and Cancerlit databases. [14] [15] [16] [17] [18] [19] [20] Also, references from research articles and textbooks were also cross-checked for any additional studies. These studies' clinical relevance were weighed against the patient population under study. Two oncologists were consulted for their expertise with regard to the appropriateness of the risk factors identified in the literature review and their opinion was sought regarding any additional potential risk factors. From the list of identified variables, a code book to identify and categorize these variables into nine unique domains (groups) was compiled.
Each domain was designed to represent plausible etiologies for the development of VOD and to stratify multiple variables into each group. The domains included patient demographics, transplant factors, medical history, induction chemotherapy, previous chemotherapy, viral serology in the recipient, health status in the 30 days prior to transplant, prophylactic medications and pretransplant laboratory values.
Statistical analysis
Descriptive analysis of patient population characteristics used summary measures including means, medians, ranges and standard deviations. Comparison of groups used crosstabulations and plots where appropriate. T-Tests for continuous variables and Fisher's exact test for comparisons of proportions were calculated. w 2 tests for univariate analysis were applied. Forward and backward stepwise multiple logistic regressions were performed to create the final models for risk factor analysis to assess cumulative risk of developing VOD. Both forward and backward stepwise regression modeling were used to develop a final multivariate regression model. To explore possible different explanations for the data, multiple models were generated. These multiple models used clinical weights determined for each variable that could substitute for another variable having a similar underlying etiologic process within a domain. Additional variables from the univariate analysis were put into these models to determine their significance (if any) when combined with other variables and a final model was created. All patients were followed out to 100 days post-transplant. For any patient who died prior to 100 days post-transplant, the cause of death was ascertained and appropriate censorship of the Kaplan-Meier survival curve was performed. The Kaplan-Meier survival analysis was used to assess if the 100-day survival was adversely affected by the development of VOD. Stata 6.0 s software was used for statistical analysis.
Results
Incidence of VOD
VOD occurred in 26 of the 142 transplant procedures (18.3%) among 132 patients. No patient had more than one incident of VOD. The incidence of VOD varied from year to year. The highest and lowest incidences occurred in 1994 at 53.3% (8/15) and in 1995 at 11.1% (2/18), respectively. The demographics of the 26 transplants that developed VOD were indistinguishable from the transplants that did not develop VOD. Likewise, the age of transplantation was similar between those who developed VOD and those that did not (see Table 1 ). All patients developed VOD prior to 20 days post-transplantation. Three patients died of causes directly attributable to VOD (see Table 2 ). Two had autopsies performed and were diagnosed with VOD based on its known associated histopathological findings. Autopsy findings included, 'diffuse hepatocyte necrosis' and 'central veins with most centrilobular areas replaced by hemorrhage or loose relatively acellular fibrous stroma'. No patient routinely had biopsies for hepatic histopathology.
Malignancy was the primary indication for HSC transplants in the majority of patients accounting for 124 of the 142 transplants (87%). The remaining 18 transplants (13%) were performed because of nonmalignant indications. Of the malignant etiologies, hematologic malignancies accounted for approximately 67%, solid tumors accounted for 27% and CNS tumors accounted for the remaining 6%. Of the 18 transplants because of nonmalignant etiologies, two were of metabolic origin, 15 of hematologic origin, and one had severe combined immunodeficiency (see Table 1 ).
Results of univariate analysis of risk factors
Of the variables reviewed, 10 risk factors were identified to be associated with a statistically increased risk for the development of VOD (see Table 3 ). These risk factors included type of transplant, history of pancreatitis, positive cytomegalovirus (CMV) serology in the recipient, diarrhea in the 30 days prior to transplant, fever in the 30 days prior to transplant, TPN in the 30 days prior to transplant, induction with busulfan, induction with fludarabine, induction with busulfan plus cyclophosphamide and GVHD medication prophylaxis. Each of these putative risk factors had a P-value of p0.05 or very close to it in the case of induction with busulfan.
Other induction regimens were assessed both as individual agents and in various combinations, but were not found to increase or decrease the risk of developing VOD in this cohort (see Table 4 ). Fisher's exact test results are also given in Table 4 , for they could be derived from the information from the table to help verify the results. The slight disparity of results between logistic regression and Fisher's exact P-values is because of methodological differences in generating the results, with logistic regression using an approximation technique vs using exact numbers in Fisher's test.
Results of multivariate analysis
The putative risk factors from the univariate analysis were then taken to develop a multivariate logistic regression model for further comprehensive explanations of VOD development in this patient population. By taking into account multiple risk factors, their interactions and cumulative risk factors can be assessed and used to try to predict who may develop VOD in the future. transplant' OR 3.40 (1.17, 9.86). The last three variables measured the presence or absence of these risk factors (see Table 5 ).
Predictions of probabilities of developing VOD with 95% CIs were created using the multiple regression variables. The predictions reflect the increased risk of developing VOD in the various allogenic transplants compared to autologous transplants in conjunction with the other identified risk factors found in this study. The overall risk of developing VOD increases with the more risk factors present (see Table 6 ).
Survival analysis
Survival at 100 days post-transplant was measured to determine if the risk of mortality was significantly different between transplant patients that developed VOD and those that did not develop VOD. Out of the entire population of 142 transplants, 21 did not survive past 100 days. In total, 10 of these transplants had previously developed VOD and 11 had not. The causes of death among the VOD-positive group were infection (four), VOD (three), multisystem organ dysfunction (one), relapse of disease (one) and chemotherapy toxicity (one). The causes of death among the VOD-negative group were relapse (four), infection (two), GVHD (one), chemotherapy toxicity (one), posttransplant lymphoproliferative disease (one), multisystem organ dysfunction (one) and unknown because of loss of follow-up (one). The first death occurred 12 days after transplantation and the last two deaths occurred on day 100 posttransplant. The Log-Rank test for equality of survival functions compared the VOD-positive and VOD-negative transplant survival curves and found them to be significantly different (Po0.001). The survival curves did not cross beyond the first two deaths and separated increasingly over the 100-day follow-up (see Figure 1) . The hazard ratio, indicating the risk of death in the VOD positive group compared to the VOD negative group, was 4.97 with a 95% confidence interval of (2.11, 11.71) (Po0.001). The survival function revealed that 90.5% of VOD-negative transplants survived past 100 days in contrast to the VOD-positive transplants where only 61.5% survived past 100 days.
Discussion
This historical cohort study investigated the incidence, risk factors of VOD and resultant 100-day survival of pediatric HSC transplant recipients over a seven and one half-year period. This is the first study to assess a very heterogeneous pediatric patient population with respect to underlying diseases and induction chemotherapies.
The 18.3% incidence of VOD in this mixed pediatric HSC transplant population fell in the mid-range of the recorded incidences found in earlier pediatric studies. Most of these studies looked at very defined patient populations with respect to either the type of malignancy (or nonmalignancy) transplanted for and/or the chemotherapeutic induction regimen used. As a result, these investigators could only safely make generalizations to other patient populations with the same underlying diseases and/or chemotherapeutic induction regimens. This is beneficial to patients with similar condition(s) and/or medication regimen(s). However, it restricted the authors from extrapolating their findings to patients with different diseases and/or induction regimens. The design of this study, with its broader patient parameters, presents a useful means of providing general predictions for those who do not fit into any previously studied group and may provide useful predictions until further studies on all of the various patient populations are performed (see Table 6 ).
Owing to the small number of patients that had any specific profile of underlying disease and induction chemotherapy, no direct comparisons with other studies were attempted. On univariate analysis, 10 variables from six different domains were identified as potential risk factors for the development of VOD. These are identified in Table 3 . These variables were taken and used for the stepwise multivariate analysis.
The 'type of transplant' variable represented the transplant factors domain. Autologous transplant was the baseline category. Compared to this baseline, a matched unrelated donor (MUD) transplant had an increased odds of 4.8 of developing VOD compared to having had an autologous transplant, assuming all other factors were equal. This finding has been similarly described in adult but not pediatric HSC transplant patients. 21 A possible underlying reason as to why matched unrelated transplants are at higher risk for developing VOD may be related to the immunological stimulation that the body elicits from the new hematopoietic stem cells. These new stem cells recognize various tissues of the patient as foreign and may act against them in a similar manner to GVHD. 22, 23 However, the histopathology of VOD and hepatic GVHD are not the same. VOD is characterized by sinusoidal changes beginning with monocytes entering into the sinusoids after the endothelium is disrupted, which worsens obstruction of the sinusoids. Subsequently, stimulation of stellate cells and production of collagen leads to the late signs of hepatic venular narrowing in the form of eccentric luminal narrowing, phlebosclerosis, sinusoidal fibrosis and/ or necrosis of zone 3 hepatocytes surrounding hepatic venules, and nodular regeneration and hyperplasia. 12 In addition to this, elevations of serum cytokines, IL-8 and TNF-a have also been found to be elevated in association with VOD. 24, 25 In comparison, GVHD is defined histologically as degenerative and destructive changes of the small interlobular or marginal bile ducts with irregular narrowing of the bile duct lumen, nuclear hyperchromasia, segmental dropout of epithelial cells, cytoplasmic swelling or eosinophilia, and apoptosis. Often accompanying these histological features are a mixed chronic inflammatory infiltrate in the portal space, hepatocellular cholestasis in zone 3 and proliferation of dilated periportal cholangioles containing inspissated bile. 26 'History of pancreatitis' represented the medical history domain. This could be representative of toxicity or adverse reactions to previous medications or chemotherapy and consequently could be a marker to identify patients at increased risk for toxicity or adverse reactions, such as VOD, during the transplant process. 'Positive CMV serology in the recipient' pretransplant represented the viral serology domain. The odds of developing VOD with a positive CMV serology pretransplant were 2.93 times the odds of developing VOD in a negative CMV serology recipient pretransplant. This is the first observation that positive CMV serology in the recipient pretransplant is a risk factor for the development of VOD in a pediatric HSC transplant population. This hepatotoxic virus might reactivate during the period of profound transplant-related immunosuppression and either cause direct damage to hepatocytes or vascular epithelium or cause damage indirectly, secondary to cytokine activation. This toxicity has been shown experimentally in rat models 27, 28 and clinically in immunocompromised and immunosuppressed patients. 29, 30 One mechanism may be through CMV immediate early gene expression in vascular smooth muscle causing neointimal thickening. 31 However, it has not specifically been shown in relation to VOD, and disseminated CMV infection has not been found in the majority of post-HSC transplant patients who do develop VOD. This new finding will need to be verified through further investigation.
'TPN pretransplant' was a variable in the 'health in the 30 days prior to transplantation' domain. Upon inspection of the data, it was noted that TPN was administered to patients only in the week preceding the HSC transplant. The other variables in the 'health in the 30 days prior to transplantation domain', 'fever' and 'diarrhea', occurred at any point in the previous 30 days and may have resolved prior to transplantation. Only the variable, 'TPN pretransplant', was consistently present immediately prior to transplant. Accordingly, this variable was the most indicative of the individual's health status immediately prior to the HSC transplant. No difference in body mass index was found between patients that received TPN immediately prior to transplant and those that did not. This implies that there were no long-standing nutritional differences between those that received TPN immediately prior to transplant and those that did not. The most common reason for providing TPN was the patient's inability to take in their caloric requirements orally. This inability was usually the result of acute and severe nausea, vomiting, anorexia or mucositis caused by the induction medications. These adverse reactions from the induction chemotherapy medications (such as cyclophosphamide) could have contributed to the underlying aetiology of why TPN provided pretransplant was associated with an increased odds of developing VOD, or it could have been related to intrinsic properties of the TPN that is known to cause cholestasis and liver disease. However, considering significant TPN-induced liver disease usually takes longer to develop than the 2-3 weeks seen between the onset of use and the development of VOD, it is more likely that TPN use is an indicator of severity of illness rather than directly causing the VOD.
The 'induction chemotherapy' domain had three variables associated with an increased odds ratio for the development of VOD on multivariate analysis.
'Busulfan' was one induction medication found on univariate analysis to be a potentially significant risk factor for the development of VOD. Busulfan's odds ratio was 2.59 with 95% confidence intervals of 0.97-6.89. Although its 95% confidence intervals did include 1.00, this variable had been found to be a significant risk factor for the development of VOD in previous studies. 6, 14 The proposed mechanism by which busulfan may increase the risk of VOD is through glutathione depletion at high doses. 32 A previous study found that a greater area under the time to serum concentration curve after medication dosage was significantly correlated with an increased risk of developing VOD. 33 The induction chemotherapy variable 'busulfan plus cyclophosphamide' had an odds ratio of 3.91 with 95% confidence intervals of 1.32-11.53. This combination induction chemotherapy regimen had been previously investigated in one pediatric study, where it found a 28% incidence of VOD. 2 In that study, it was proposed that an interaction between cyclophosphamide and busulfan increased the toxicity of busulfan, thereby increasing the risk of developing VOD. 2 Other studies in vitro that have investigated the effects of this combination have found that busulfan influences the metabolism of cyclophosphamide, thus increasing the relative concentrations of cyclophosphamide's toxic metabolites. It has been shown that a greater area under the curve for these metabolites is also associated with the development of VOD. 34, 35 'Fludarabine' was the third variable in the induction chemotherapy domain to appear to be a significant predictor for the development of VOD in this cohort. This is a new finding. However, since only nine patients received fludarabine in this patient population, confirmation of this finding with other studies is required.
'GVHD prophylaxis' was the only regimen in the 'prophylactic medications' domain that was found to predict the outcome of the development of VOD. Therefore, it was the only appropriate risk factor to represent the prophylactic medication given during transplant process domain. Statistically, this variable is very similar to the 'type of transplant' risk factor. The baselines for both variables included almost the exact same patients because of the fact that none of the autologous transplants received any GVHD prophylaxis. Upon inspection, the only nonautologous patients that did not receive GVHD prophylaxis were identically matched siblings. The specific medications used for GVHD prophylaxis in this patient population have not been previously associated with the development of VOD. Other factors associated with autologous vs allogenic transplants, such as underlying diseases and induction regimens, may be confounding this apparent association.
Forward and backward modeling was performed utilizing a combination of clinical, theoretical and statistical significances. Univariate risk factors that became nonsignificant when combined with other variables in the model building process were dropped from the final model.
As a result, the final model for this cohort therefore had the following variables, type of transplant, positive CMV serology, TPN provided pretransplant and induction with busulfan (see Table 5 ).
The survival analysis compared the 100-day survival of transplants that developed VOD vs those that did not develop VOD. The rate of death in the VOD-positive group was almost five times the rate in the VOD negative group. Since the survival curves did not cross beyond the first two deaths, the survival function did not reverse over time and thus the risk of death was always greater for the VODpositive group (Figure 1 ). From these data it could be extrapolated, that if the development of VOD increases a patient's risk of death in the first 100 days post-transplant, then decreasing the risk factors for VOD should improve the 100-day survival in this patient population.
This study contributes new and additional information to the existing literature regarding VOD in a mixed North American Pediatric HSC post-transplant population. The variety of indications for HSC transplantation, induction regimens and previous therapy will reflect populations in other centers, which increases the utility and value of the 100-day survival findings.
This study identified two new statistically significant putative risk factors, TPN pretransplant and positive CMV serology in the transplant recipient, for the development of VOD in this pediatric HSC transplantation population.
The results of this study can assist in planning new prospective studies that alter modifiable risk factors (such as the induction chemotherapy regimen or dosing of the regimens to reduce the side effects that necessitate the use of TPN in the week prior to transplant), and assess if altering these risk factors reduces the incidence of VOD in a pediatric HSC transplant population.
Techniques similar to the ones used in this study could also be utilized to identify risk factors for other adverse outcomes associated with HSC transplantation, such as GVHD.
Prophylactic therapy with ursodeoxycholic acid has been shown to be both safe and effective in decreasing the incidence of VOD in the adult HSC transplant population. [36] [37] [38] A double-blind, placebo-controlled trial investigating this prophylactic therapy needs to be performed in pediatric patients to see if the same holds true.
In summary, the impacts on clinical care from this study are two-fold. First, the results can be used to identify highrisk patients who are to undergo an HSC transplant. Second, it can facilitate clinicians in counselling those contemplating HSC transplantation and their families as to what the general risks in pediatric patients are for developing VOD and for what the risks might be in their particular circumstance.
This study separates itself from previous studies with its heterogeneous population of patients and induction regimens. It provides an informed overall risk of VOD to all pediatric patients that underwent HSC transplantation. From this study, general predictions for VOD in future applicable patients can be made, at least until more studies become available to predict the risk of development of VOD for each individual underlying disease and/or specific medication regimen.
